{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:00:04Z","timestamp":1765422004840},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ctrv.2016.11.005","type":"journal-article","created":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T07:59:06Z","timestamp":1479283146000},"page":"41-47","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis"],"prefix":"10.1016","volume":"52","author":[{"given":"F.","family":"Malard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Harousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2016.11.005_b0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2016.11.005_b0010","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","article-title":"Curing myeloma at last: defining criteria and providing the evidence","volume":"124","author":"Barlogie","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2016.11.005_b0015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","article-title":"Long-term prognostic significance of response in multiple myeloma after stem cell transplantation","volume":"118","author":"Martinez-Lopez","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2016.11.005_b0020","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2016.11.005_b0025","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2016.11.005_b0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/leu.2011.310","article-title":"Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and \u2018retreatment\u2019 approaches in the era of novel agents","volume":"26","author":"Mohty","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2016.11.005_b0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0609.2008.01121.x","article-title":"A systematic review of phase II trials of thalidomide\/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma","volume":"81","author":"von Lilienfeld-Toal","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0040","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1600-0609.2012.01775.x","article-title":"Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study","volume":"88","author":"Hjorth","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0045","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1182\/blood-2011-04-350009","article-title":"Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma","volume":"118","author":"Madan","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2016.11.005_b0050","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bjh.12198","article-title":"A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma","volume":"160","author":"Petrucci","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0055","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1200\/JCO.2007.14.2372","article-title":"Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma","volume":"26","author":"Reece","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0060","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1365-2141.2007.06656.x","article-title":"Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma","volume":"138","author":"Kropff","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0065","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1038\/bcj.2013.58","article-title":"Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study","volume":"3","author":"Offidani","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctrv.2016.11.005_b0070","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2141.2008.07572.x","article-title":"Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma","volume":"144","author":"Popat","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0075","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0080","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","volume":"30","author":"Garderet","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0085","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1182\/blood-2013-07-517276","article-title":"A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed\/refractory myeloma","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2016.11.005_b0090","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0095","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","author":"Dimopoulos","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0105","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.11.005_b0110","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.11.005_b0115","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2016.11.005_b0120","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.11.005_b0125","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2016.11.005_b0130","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2016.11.005_b0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0140","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cardfail.2014.11.008","article-title":"Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma","volume":"21","author":"Grandin","year":"2015","journal-title":"J Card Fail"},{"key":"10.1016\/j.ctrv.2016.11.005_b0145","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.11.005_b0150","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2016.11.005_b0155","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.11.005_b0160","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2016.11.005_b0165","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-07-726729","article-title":"Phase 1\/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma","author":"Plesner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2016.11.005_b0170","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.11.005_b0175","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.11.005_b0180","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2016.11.005_b0185","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2016.11.005_b0190","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0195","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","article-title":"Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma","volume":"128","author":"Dimopoulos","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2016.11.005_b0200","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2141.2005.05521.x","article-title":"Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma","volume":"129","author":"Kyriakou","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0205","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2141.2010.08250.x","article-title":"The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed\/refractory myeloma patients; a phase I\/II study","volume":"150","author":"Schey","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0210","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bjh.13100","article-title":"Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma","volume":"168","author":"Reece","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0215","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(14)70245-1","volume":"15","author":"Cook","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0220","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0225","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.bbmt.2015.09.016","volume":"21","author":"Giralt","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ctrv.2016.11.005_b0230","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1002\/cncr.25228","article-title":"Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up","volume":"116","author":"Shimoni","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2016.11.005_b0235","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bbmt.2011.07.026","article-title":"Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability","volume":"18","author":"Patriarca","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ctrv.2016.11.005_b0240","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/bmt.2013.73","article-title":"Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation","volume":"48","author":"Auner","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ctrv.2016.11.005_b0245","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3324\/haematol.2009.015917","article-title":"Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma","volume":"95","author":"Harousseau","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2016.11.005_b0250","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2008.07303.x","article-title":"The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma","volume":"143","author":"Niesvizky","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0255","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/leu.2010.175","article-title":"Treatment of patients with relapsed\/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies","volume":"24","author":"Dimopoulos","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2016.11.005_b0260","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2016.11.005_b0265","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","article-title":"Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"30","author":"Lonial","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0270","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1200\/JCO.2012.46.7068","article-title":"Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma","volume":"31","author":"San-Miguel","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0275","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","article-title":"Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study","volume":"123","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2016.11.005_b0280","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/asheducation-2010.1.489","article-title":"Ultra high-risk myeloma","volume":"2010","author":"Avet-Loiseau","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.ctrv.2016.11.005_b0285","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1200\/JCO.2013.53.0329","volume":"32","author":"Moreau","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0290","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2016.11.005_b0295","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1600-0609.2009.01385.x","article-title":"Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA","volume":"84","author":"Morabito","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0300","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","article-title":"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients","volume":"124","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2016.11.005_b0305","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1211\/0022357022241","article-title":"Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis","volume":"55","author":"Eriksson","year":"2003","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0310","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3324\/haematol.2015.137083","article-title":"Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low \u2013 dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma","volume":"101","author":"Weisel","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2016.11.005_b0315","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1681\/ASN.2012060590","article-title":"Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase","volume":"24","author":"Zhong","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0320","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.ajpath.2011.01.044","article-title":"Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism","volume":"178","author":"Advani","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0325","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.clml.2015.12.007","article-title":"Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study","volume":"16","author":"Berdeja","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.ctrv.2016.11.005_b0330","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2016.11.005_b0335","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/sj.thj.6200003","article-title":"Are myeloma patients with renal failure candidates for autologous stem cell transplantation?","volume":"1","author":"San Miguel","year":"2000","journal-title":"Hematol J"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2016.11.005_b0340","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S0049-3848(16)30103-7","article-title":"Update of thrombosis in multiple myeloma","volume":"140","author":"Leebeek","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.ctrv.2016.11.005_b0345","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European myeloma network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2016.11.005_b0350","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/bmt.2008.180","article-title":"Impact of early relapse after auto-SCT for multiple myeloma","volume":"42","author":"Kumar","year":"2008","journal-title":"Bone Marrow Transplant"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216301219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737216301219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T12:36:16Z","timestamp":1568550976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737216301219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":70,"alternative-id":["S0305737216301219"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.11.005","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple myeloma treatment at relapse after autologous stem cell transplantation: A practical analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2016.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}